Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gocatamig (HPN328) in DLL3-expressing Advanced Cancers
NCT04471727Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of gocatamig in small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), neuroendocrine carcinoma (NEC), sponsored by Merck & Co.. Started Dec 2020; status: active, not recruiting.
02
Drugs
gocatamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine prostate cancer (NEPC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04471727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471727.